These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11642477)

  • 21. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder.
    Carminati GG; Gerber F; Darbellay B; Kosel MM; Deriaz N; Chabert J; Fathi M; Bertschy G; Ferrero F; Carminati F
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Feb; 65():85-95. PubMed ID: 26361994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism.
    Hellings JA; Zarcone JR; Crandall K; Wallace D; Schroeder SR
    J Child Adolesc Psychopharmacol; 2001; 11(3):229-38. PubMed ID: 11642473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zuclopenthixol, melperone and haloperidol/levomepromazine in the elderly. Meta-analysis of two double-blind trials at 15 nursing homes in Norway.
    Nygaard HA; Fuglum E; Elgen K
    Curr Med Res Opin; 1992; 12(10):615-22. PubMed ID: 1353014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
    Zalsman G; Carmon E; Martin A; Bensason D; Weizman A; Tyano S
    J Child Adolesc Psychopharmacol; 2003; 13(3):319-27. PubMed ID: 14642020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychopathology and mental retardation: A study of 100 mentally retarded children: I. Psychopathology.
    Philips I; Williams N
    Am J Psychiatry; 1975 Dec; 132(12):1265-71. PubMed ID: 1200170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
    Aman MG; De Smedt G; Derivan A; Lyons B; Findling RL;
    Am J Psychiatry; 2002 Aug; 159(8):1337-46. PubMed ID: 12153826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study.
    Ercan ES; Uysal T; Ercan E; Akyol Ardic U
    Pharmacopsychiatry; 2012 Jan; 45(1):13-9. PubMed ID: 21993869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice.
    Manzaneque JM; Navarro JF
    Methods Find Exp Clin Pharmacol; 1999; 21(1):11-5. PubMed ID: 10222441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open multicentre trial of zuclopenthixol in mania and schizophrenia based on the AMDP scales.
    Bobon D; Troisfontaines B; Kempeneers JL; Xhenseval B; Bourdouxhe S; Mirel J; Gilson H; Toussaint C; von Frenckell R; Pedersen V
    Acta Psychiatr Belg; 1986; 86(2):152-76. PubMed ID: 2873713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Experiences with psychopharmaceutic agents in mentally retarded children].
    Dosen A
    Tijdschr Kindergeneeskd; 1982 Feb; 50(1):10-9. PubMed ID: 6124053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of zuclopenthixol in the treatment of aggression in Huntington's disease.
    Tibrewal P; Bastiampillai T; Dhillon R; Cheng R; Fonseka HT
    Asian J Psychiatr; 2017 Apr; 26():152-153. PubMed ID: 28483083
    [No Abstract]   [Full Text] [Related]  

  • 32. The management of chronic behavior disorders in mentally retarded adults with lithium carbonate.
    Sovner R; Hurley A
    J Nerv Ment Dis; 1981 Mar; 169(3):191-5. PubMed ID: 6782191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depression in mentally retarded children.
    Matson JL; Barrett RP; Helsel WJ
    Res Dev Disabil; 1988; 9(1):39-46. PubMed ID: 3353541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of intermittent drug therapy on stereotypy and collateral behaviors of mentally retarded persons.
    Millichamp CJ; Singh NN
    Res Dev Disabil; 1987; 8(2):213-27. PubMed ID: 2890189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurobehavioral assessment of children and adolescents attending a developmental disabilities clinic.
    Brasić JR; Barnett JY; Kowalik S; Tsaltas MO; Ahmad R
    Psychol Rep; 2004 Dec; 95(3 Pt 2):1079-86. PubMed ID: 15762388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Off-label second generation antipsychotics for impulse regulation disorders: a review.
    Scheltema Beduin A; de Haan L
    Psychopharmacol Bull; 2010; 43(3):45-81. PubMed ID: 21150846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zuclopenthixol acetate treatment in children with bipolar disorder and severe aggression.
    Ercan ES; Ardiç UA; Kandulu R; Yektas C
    J Clin Psychopharmacol; 2011 Jun; 31(3):397-8. PubMed ID: 21532374
    [No Abstract]   [Full Text] [Related]  

  • 39. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy.
    Klampfl K; Taurines R; Preuss A; Burger R; Rothenhöfer S; Wewetzer Ch; Pfuhlmann B; Fegert J; Gerlach M; Mehler-Wex C
    Pharmacopsychiatry; 2010 Mar; 43(2):58-65. PubMed ID: 20336598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.